High-profile $43 billion agriculture deal faces lengthier regulatory review
ChemChina announces changes to the financing of its planned $43B purchase of Syngenta, likely ensuring a lengthier review by regulators around the world, including the U.S. Committee on Foreign Investment.
The planned deal, unveiled in February, would rank as the biggest-ever foreign acquisition by a Chinese company and would supercharge China’s effort to develop its domestic seed industry – a key part of the chinese government’s strategy to secure food supplies as domestic consumption grows.
It is one of several mergers in the Works that would reshape the $100 billion global market for crop seed and pesticide, as three straight years of declining prices for major crops have pressured profits and forced companies to scale back staff and research.
The Chinese company says it has secured a $5B investment from an arm of one of state-owned conglomerate Citic, which will allow it to reduce its reliance on loans to finance the deal.
ChemChina’s continued effort to secure financing for the deal has weighed on SYT shares, which have traded at a steep discount to the offer price.
You might also be interested in:
We are at the precipice of a new decade of change for women. As 2020 creates new promises across different socio-economic fronts, this decade will embrace and welcome women’s role in government, politics, business and corporate leadership in a way that normalises their presence and influence in otherwise homogeneous male environments.
We find ourselves in a time that is unfortunately affected in all aspects of our lives by an invisible threat. It’s a threat that not only affects human health, but has entered people's minds with devastating effect, upsetting their psychological balance and the economic health of society, and as a result posing existential questions by part of the population itself.